United Therapeutics (NASDAQ:UTHR) Price Target Lowered to $701.00 at Royal Bank Of Canada

United Therapeutics (NASDAQ:UTHR) had its price target reduced by analysts at Royal Bank Of Canada from $707.00 to $701.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 22.13% from the company’s previous close.

UTHR has been the subject of several other reports. Wells Fargo & Company set a $735.00 price objective on United Therapeutics and gave the stock an “overweight” rating in a research report on Thursday. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Cantor Fitzgerald increased their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, HC Wainwright boosted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Down 3.8%

Shares of NASDAQ UTHR traded down $22.78 during midday trading on Thursday, hitting $573.98. The stock had a trading volume of 380,429 shares, compared to its average volume of 479,562. United Therapeutics has a 1 year low of $272.12 and a 1 year high of $609.35. The company has a market capitalization of $24.26 billion, a PE ratio of 20.56, a P/E/G ratio of 1.63 and a beta of 0.60. The stock has a 50 day simple moving average of $548.25 and a 200-day simple moving average of $500.41.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business posted $6.63 EPS. As a group, analysts expect that United Therapeutics will post 27.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $576.97, for a total transaction of $5,481,215.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $23,374,785.61. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher Patusky sold 2,910 shares of United Therapeutics stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of $569.00, for a total transaction of $1,655,790.00. Following the completion of the transaction, the director owned 1,490 shares of the company’s stock, valued at $847,810. This trade represents a 66.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 467,355 shares of company stock worth $255,900,484 over the last three months. Company insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC raised its holdings in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Wellington Management Group LLP increased its position in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Finally, Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics during the 3rd quarter worth $317,617,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on strong clinical readouts and pipeline potential — market commentary highlights positive Tyvaso data in IPF and ralinepag’s “blockbuster” potential, which helped sentiment despite the quarter’s misses. UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
• Positive Sentiment: Several analysts have raised price targets and maintain buy/overweight views, supporting longer-term upside expectations and cushioning the selloff. Analyst Coverage and Price Targets on UTHR
• Neutral Sentiment: The company filed its official Q1 release and slide deck providing detail on results and ongoing trials; useful for investors but not market-moving by itself. United Therapeutics Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Expansion of a DPI partnership (reported in coverage of MannKind’s stock move) signals continued device/partnership activity that could be incremental to UTHR’s inhaled product strategy, though the immediate impact on UTHR revenue is unclear. MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership
• Negative Sentiment: United Therapeutics missed EPS and revenue estimates for Q1 (EPS $5.82 vs. consensus, revenue $781.5M below estimates), creating short-term pressure as results fell short of expectations. UTHR Misses Q1 Estimates
• Negative Sentiment: Insider selling: CEO Martine Rothblatt and CFO James Edgemond disclosed sizable sales on May 4, which can weigh on sentiment and raise questions for some investors about near-term insider conviction. Insider Sales by UTHR Executives

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.